The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells

• Main Authors: Michel Demeule (Author), Cyndia Charfi (Author), Jean-Christophe Currie (Author), Alain Zgheib (Author), Bogdan Alexandru Danalache (Author), Richard Béliveau (Author), Christian Marsolais (Author), Borhane Annabi (Author)
• Format: Book
• Published: MDPI AG, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

<b>Background:</b> Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. Whether TH1902 impacts the chemore...